These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17724008)

  • 1. Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases.
    Anastasilakis AD; Goulis DG; Kita M; Avramidis A
    Hormones (Athens); 2007; 6(3):233-41. PubMed ID: 17724008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety considerations with bisphosphonates for the treatment of osteoporosis.
    Strampel W; Emkey R; Civitelli R
    Drug Saf; 2007; 30(9):755-63. PubMed ID: 17722968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
    Blumentals WA; Harris ST; Cole RE; Huang L; Silverman SL
    Ann Pharmacother; 2009 Apr; 43(4):577-85. PubMed ID: 19318598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yearly zoledronic acid in postmenopausal osteoporosis.
    Karam R; Camm J; McClung M
    N Engl J Med; 2007 Aug; 357(7):712-3; author reply 714-5. PubMed ID: 17703529
    [No Abstract]   [Full Text] [Related]  

  • 5. Risedronate: a new oral bisphosphonate.
    Umland EM; Boyce EG
    Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
    Binkley N; Martens MG; Silverman SL; Derman RJ; Greenwald M; Kohles JD; Bachmann GA
    South Med J; 2009 May; 102(5):486-92. PubMed ID: 19373149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative gastrointestinal safety of weekly oral bisphosphonates.
    Cadarette SM; Katz JN; Brookhart MA; Stürmer T; Stedman MR; Levin R; Solomon DH
    Osteoporos Int; 2009 Oct; 20(10):1735-47. PubMed ID: 19266138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity.
    Kharazmi M; Persson U; Warfvinge G
    J Oral Maxillofac Surg; 2012 Dec; 70(12):2793-7. PubMed ID: 22609135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upper gastrointestinal tolerability of alendronate sodium monohydrate 10 mg once daily in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled, exploratory study.
    Adachi JD; Faraawi RY; O'Mahony MF; Nayar A; Massaad R; Evans JK; Yacik C
    Clin Ther; 2009 Aug; 31(8):1747-53. PubMed ID: 19808133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
    Ste-Marie LG; Brown JP; Beary JF; Matzkin E; Darbie LM; Burgio DE; Racewicz AJ
    Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.
    Kherani RB; Papaioannou A; Adachi JD
    Drug Saf; 2002; 25(11):781-90. PubMed ID: 12222989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
    Fitzpatrick SG; Stavropoulos MF; Bowers LM; Neuman AN; Hinkson DW; Green JG; Bhattacharyya I; Cohen DM
    J Oral Maxillofac Surg; 2012 Feb; 70(2):325-30. PubMed ID: 21723015
    [No Abstract]   [Full Text] [Related]  

  • 14. Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.
    Gopal GK; Tam KL; Krishnan SP; Maddern IL
    N Z Med J; 2014 Feb; 127(1389):81-5. PubMed ID: 24548959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.
    Iizuka T; Matsukawa M
    Climacteric; 2008 Aug; 11(4):287-95. PubMed ID: 18645694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral bisphosphonate-related osteonecrosis of the jaws in dental implant patients: a case series.
    López-Cedrún JL; Sanromán JF; García A; Peñarrocha M; Feijoo JF; Limeres J; Diz P
    Br J Oral Maxillofac Surg; 2013 Dec; 51(8):874-9. PubMed ID: 23866309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
    Ralston SH; Kou TD; Wick-Urban B; Steinbuch M; Masud T
    Calcif Tissue Int; 2010 Oct; 87(4):298-304. PubMed ID: 20803291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.
    Malden NJ; Pai AY
    Br Dent J; 2007 Jul; 203(2):93-7. PubMed ID: 17660780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
    Stovall DW; Beard MK; Barbier S; Chen E; Rosenberg E; de Papp AE
    J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.